AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Amneal Pharmaceuticals, Inc.

$17.01 +$4.35 (+34.36%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$16.87
Day Range
$16.75$17.11
Year Range
$9.49$19.26
Market Cap
5.43B
AVG Volume
1.87M
Trailing/Forward PE
34.19/14.49
PEG ratio
2.16
Dividend Yield
-
Next Earnings Date
2026-10-29
Primary Exchange
NASDAQUS
Revenue (USD)
01B2B3B4B201720182019202020212022202320242025
AMRX Revenue (USD) by year
PeriodRevenue (USD)
20253.02B
20242.79B
20232.39B
20222.21B
20212.09B
20201.99B
20191.63B
20181.66B
20171.03B
Net Income (USD)
-400M-200M0200M201720182019202020212022202320242025
AMRX Net Income (USD) by year
PeriodNet Income (USD)
202572.06M
2024-116.89M
2023-83.99M
2022-129.99M
202110.62M
202091.06M
2019-361.92M
2018-169.73M
2017168.06M
Operating Income (USD)
-400M-200M0200M400M201720182019202020212022202320242025
AMRX Operating Income (USD) by year
PeriodOperating Income (USD)
2025326.1M
2024249.33M
2023204.37M
2022-94.93M
2021152.72M
202091.16M
2019-248.68M
2018-19.67M
2017245.1M
EBITDA (USD)
0200M400M600M800M201720182019202020212022202320242025
AMRX EBITDA (USD) by year
PeriodEBITDA (USD)
2025603.87M
2024439.77M
2023399.76M
2022150.43M
2021401.1M
2020345.61M
2019155.2M
2018108.64M
2017284.52M
Cash Flows (USD)
-200M0200M400M201720182019202020212022202320242025
AMRX Cash Flows (USD) by year
PeriodCash Flows (USD)
2025236.95M
2024220.86M
2023276.39M
2022-35.8M
2021193.54M
2020316.12M
2019-95.73M
2018153.14M
2017119.92M
EPS (USD)
-4-202201720182019202020212022202320242025
AMRX EPS (USD) by year
PeriodEPS (USD)
20250.22
2024-0.38
2023-0.33
2022-0.9
20210.07
20200.62
2019-2.76
2018-1.3
20171.38
Expenses (USD)
0250M500M750M1BR&DSG&ACapex201720182019202020212022202320242025
AMRX Expenses (USD) by year
PeriodExpenses (USD)
2025819.83M
2024744.28M
2023666.64M
2022656.65M
2021623.35M
2020580.2M
2019589.32M
2018535.62M
2017409.09M
Cash & Debt (USD)
01B2B3BCashLong Term DebtShort Term Debt201720182019202020212022202320242025
AMRX Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025310.87M
2024112.42M
202393.74M
202227.8M
2021248.96M
2020343.07M
2019152.32M
2018213.39M
201774.17M
Debt ratios
0123202020212022202320242025
AMRX Debt ratios by year
PeriodDebt ratios
20251.52
20241.78
20232.05
20222.68
20212.61
20202.97
Margins
0%20%40%60%201720182019202020212022202320242025
AMRX Margins by year
PeriodMargins
202536.88%
202436.52%
202335.77%
202235.47%
202136.73%
202031.54%
201921.7%
201843.08%
201750.31%
Return on Capital
-500%0%500%1000%1500%201720182019202020212022202320242025
AMRX Return on Capital by year
PeriodReturn on Capital
20251208.4%
2024262.44%
2023-137.01%
2022-62.22%
20212.77%
202025.53%
2019-104.36%
2018-13.18%
2017-44.75%
Shares Outstanding
0100M200M300M400M201720182019202020212022202320242025
AMRX Shares Outstanding by year
PeriodShares Outstanding
2025313.37M
2024309.85M
2023243.71M
2022151.48M
2021149.37M
2020147.64M
2019141.6M
2018127.34M
2017114.86M
Book Value Per Share (USD)
-5051015201720182019202020212022202320242025
AMRX Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20250.02
2024-0.14
20230.25
20221.38
20212.57
20202.42
20192.45
201810.11
2017-3.27
Total Assets (USD)
02B4B6B201720182019202020212022202320242025
AMRX Total Assets (USD) by year
PeriodTotal Assets (USD)
20253.68B
20243.5B
20233.47B
20223.8B
20213.94B
20204.01B
20193.67B
20184.35B
20171.34B
Employee Count
02.5K5K7.5K10K20182019202020212022202320242025
AMRX Employee Count by year
PeriodEmployee Count
20258.5K
20248.1K
20237.7K
20227.6K
20217K
20206K
20195.5K
20186K
PE Ratio
025050075010001250med 86.05Apr 22Nov 23Feb 24Oct 25Feb 26May 26Sep 26
AMRX PE Ratio by year
PeriodPE Ratio
Sep 2634.5
Sep 2635.38
Aug 2635.58
Aug 2636.33
Aug 2636.82
Aug 2636.8
Jul 2647.41
Jul 2646.37
Jul 2646.19
Jul 2644.02
Jul 2644.38
Jun 2644.59
Jun 2641.95
Jun 2641.92
Jun 2635.58
May 2634.08
May 2632.14
May 2630.87
May 2634.16
May 2655.8
Apr 2654.45
Apr 2660.49
Apr 2654.53
Apr 2654.27
Mar 2651.53
Mar 2651.45
Mar 2651.45
Mar 2657.58
Feb 2660.06
Feb 26772.11
Feb 26789.15
Feb 26773.17
Jan 26728.44
Jan 26713
Jan 26714.07
Jan 26690.1
Jan 26674.13
Dec 25689.57
Dec 25669.34
Dec 25650.17
Dec 25648.57
Nov 25666.68
Nov 25636.32
Nov 25619.82
Nov 25605.44
Oct 251005.82
Oct 25980.72
Oct 25922.16
Oct 25926.81
Oct 25965.85
Sep 25906.36
Sep 25911.93
Sep 25929.6
Sep 25894.27
Aug 25888.69
Aug 25891.48
Aug 25878.47
Aug 25793.88
Mar 2484.26
Mar 2485.51
Feb 2490.66
Feb 2492.23
Feb 2487.07
Feb 2486.29
Jan 2485.82
Jan 2484.41
Jan 2484.41
Jan 2493.63
Dec 2394.88
Dec 2390.04
Dec 2381.13
Dec 2379.1
Dec 2372.84
Nov 2370.66
Nov 2370.81
Nov 2365.97
Aug 22270.52
Jul 22301.15
Jul 22268.82
Jul 22266.27
Jul 22280.73
Jul 22285.83
Jun 22272.22
Jun 22271.37
Jun 22270.52
Jun 22296.89
May 22294.34
May 22298.59
May 22293.49
May 22289.24
Apr 2254.27
Apr 2254.97
Apr 2257.93
Apr 2262.71
Apr 2260.46
Mar 2258.35
Mar 2258.91
Mar 2257.93
Mar 2256.8
Feb 2249.07
Free Cash Flow Yield
0%2.5%5%7.5%10%12.5%med 7.97%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
AMRX Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 261.53%
Sep 261.49%
Aug 261.48%
Aug 261.45%
Aug 261.43%
Aug 261.44%
Jul 263.55%
Jul 263.62%
Jul 263.64%
Jul 263.82%
Jul 263.79%
Jun 263.77%
Jun 264.01%
Jun 264.01%
Jun 264.72%
May 264.93%
May 265.23%
May 265.44%
May 264.92%
May 265.89%
Apr 266.04%
Apr 265.44%
Apr 266.03%
Apr 266.06%
Mar 266.38%
Mar 266.39%
Mar 266.39%
Mar 265.71%
Feb 265.48%
Feb 265.37%
Feb 265.26%
Feb 265.37%
Jan 265.7%
Jan 265.82%
Jan 265.81%
Jan 266.01%
Jan 266.16%
Dec 256.02%
Dec 256.2%
Dec 256.38%
Dec 256.4%
Nov 256.22%
Nov 256.52%
Nov 256.69%
Nov 256.85%
Oct 257.73%
Oct 257.93%
Oct 258.43%
Oct 258.39%
Oct 258.05%
Sep 258.58%
Sep 258.53%
Sep 258.37%
Sep 258.7%
Aug 258.75%
Aug 258.72%
Aug 258.85%
Aug 259.8%
Aug 259.61%
Jul 259.34%
Jul 259.44%
Jul 259.04%
Jul 258.94%
Jun 259.26%
Jun 259.62%
Jun 259.71%
Jun 259.88%
May 2510.28%
May 2510.51%
May 259.9%
May 2510.16%
May 258.94%
Apr 259.53%
Apr 259.68%
Apr 2510.21%
Apr 259.66%
Mar 258.61%
Mar 258.23%
Mar 258.15%
Mar 258.01%
Feb 258.22%
Feb 259.49%
Feb 259.61%
Feb 259.46%
Jan 258.99%
Jan 258.56%
Jan 258.99%
Jan 259.32%
Jan 259.5%
Dec 249.5%
Dec 249.55%
Dec 249.49%
Dec 248.79%
Nov 248.98%
Nov 248.85%
Nov 248.77%
Nov 248.51%
Nov 246.74%
Oct 246.81%
Oct 246.67%
Price to Sales
0.511.52med 1.09Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
AMRX Price to Sales by year
PeriodPrice to Sales
Sep 261.74
Sep 261.79
Aug 261.8
Aug 261.83
Aug 261.86
Aug 261.86
Jul 261.9
Jul 261.86
Jul 261.85
Jul 261.76
Jul 261.78
Jun 261.79
Jun 261.68
Jun 261.68
Jun 261.43
May 261.37
May 261.29
May 261.24
May 261.37
May 261.33
Apr 261.3
Apr 261.44
Apr 261.3
Apr 261.3
Mar 261.23
Mar 261.23
Mar 261.23
Mar 261.37
Feb 261.43
Feb 261.55
Feb 261.59
Feb 261.55
Jan 261.46
Jan 261.43
Jan 261.44
Jan 261.39
Jan 261.36
Dec 251.39
Dec 251.35
Dec 251.31
Dec 251.3
Nov 251.34
Nov 251.28
Nov 251.25
Nov 251.22
Oct 251.19
Oct 251.16
Oct 251.09
Oct 251.1
Oct 251.14
Sep 251.07
Sep 251.08
Sep 251.1
Sep 251.06
Aug 251.05
Aug 251.05
Aug 251.04
Aug 250.94
Aug 250.86
Jul 250.89
Jul 250.88
Jul 250.92
Jul 250.93
Jun 250.89
Jun 250.86
Jun 250.85
Jun 250.84
May 250.8
May 250.79
May 250.84
May 250.81
May 250.88
Apr 250.83
Apr 250.82
Apr 250.77
Apr 250.82
Mar 250.92
Mar 250.96
Mar 250.97
Mar 250.99
Feb 250.96
Feb 250.9
Feb 250.89
Feb 250.91
Jan 250.95
Jan 251
Jan 250.95
Jan 250.92
Jan 250.9
Dec 240.9
Dec 240.9
Dec 240.9
Dec 240.98
Nov 240.96
Nov 240.97
Nov 240.98
Nov 241.01
Nov 241.01
Oct 241
Oct 241.02
EV/EBITDA
810121416med 11.37Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
AMRX EV/EBITDA by year
PeriodEV/EBITDA
Sep 2612.41
Sep 2612.62
Aug 2612.67
Aug 2612.85
Aug 2612.97
Aug 2612.96
Jul 2613.05
Jul 2612.85
Jul 2612.81
Jul 2612.39
Jul 2612.46
Jun 2612.5
Jun 2612
Jun 2611.99
Jun 2610.77
May 2610.48
May 2610.11
May 269.87
May 2610.5
May 2610.67
Apr 2610.51
Apr 2611.24
Apr 2610.52
Apr 2610.49
Mar 2610.17
Mar 2610.16
Mar 2610.16
Mar 2610.89
Feb 2611.18
Feb 2612.67
Feb 2612.85
Feb 2612.68
Jan 2612.21
Jan 2612.04
Jan 2612.05
Jan 2611.8
Jan 2611.63
Dec 2511.79
Dec 2511.58
Dec 2511.37
Dec 2511.36
Nov 2511.55
Nov 2511.23
Nov 2511.05
Nov 2510.9
Oct 2510.1
Oct 259.95
Oct 259.61
Oct 259.64
Oct 259.87
Sep 259.52
Sep 259.55
Sep 259.66
Sep 259.45
Aug 259.42
Aug 259.44
Aug 259.36
Aug 258.87
Aug 259.03
Jul 259.16
Jul 259.11
Jul 259.32
Jul 259.37
Jun 259.2
Jun 259.03
Jun 258.99
Jun 258.91
May 258.74
May 258.65
May 258.9
May 258.79
May 2511.26
Apr 2510.91
Apr 2510.83
Apr 2510.56
Apr 2510.84
Mar 2511.47
Mar 2511.74
Mar 2511.81
Mar 2511.91
Feb 2511.75
Feb 2513.86
Feb 2513.78
Feb 2513.88
Jan 2514.23
Jan 2514.59
Jan 2514.23
Jan 2513.98
Jan 2513.85
Dec 2413.85
Dec 2413.82
Dec 2413.86
Dec 2414.4
Nov 2414.24
Nov 2414.34
Nov 2414.41
Nov 2414.64
Nov 2415.08
Oct 2415.01
Oct 2415.16
Price/Operating Cashflow
0102030med 9.39Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
AMRX Price/Operating Cashflow by year
PeriodPrice/Operating Cashflow
Sep 2627.04
Sep 2627.73
Aug 2627.89
Aug 2628.47
Aug 2628.86
Aug 2628.84
Jul 2619.05
Jul 2618.64
Jul 2618.56
Jul 2617.69
Jul 2617.84
Jun 2617.92
Jun 2616.86
Jun 2616.85
Jun 2614.3
May 2613.7
May 2612.92
May 2612.41
May 2613.73
May 2611.83
Apr 2611.54
Apr 2612.82
Apr 2611.56
Apr 2611.5
Mar 2610.92
Mar 2610.9
Mar 2610.9
Mar 2612.2
Feb 2612.73
Feb 2613.9
Feb 2614.21
Feb 2613.92
Jan 2613.11
Jan 2612.83
Jan 2612.85
Jan 2612.42
Jan 2612.14
Dec 2512.41
Dec 2512.05
Dec 2511.7
Dec 2511.68
Nov 2512
Nov 2511.45
Nov 2511.16
Nov 2510.9
Oct 259.67
Oct 259.43
Oct 258.86
Oct 258.91
Oct 259.28
Sep 258.71
Sep 258.77
Sep 258.94
Sep 258.6
Aug 258.54
Aug 258.57
Aug 258.44
Aug 257.63
Aug 257.94
Jul 258.17
Jul 258.08
Jul 258.44
Jul 258.53
Jun 258.24
Jun 257.93
Jun 257.85
Jun 257.72
May 257.42
May 257.26
May 257.7
May 257.51
May 258.37
Apr 257.85
Apr 257.73
Apr 257.33
Apr 257.75
Mar 258.69
Mar 259.09
Mar 259.19
Mar 259.34
Feb 259.1
Feb 257.75
Feb 257.65
Feb 257.77
Jan 258.18
Jan 258.59
Jan 258.18
Jan 257.89
Jan 257.74
Dec 247.74
Dec 247.7
Dec 247.75
Dec 248.36
Nov 248.19
Nov 248.3
Nov 248.38
Nov 248.64
Nov 2410.4
Oct 2410.29
Oct 2410.51
Price to Book
0200400600800med 3.31Dec 22Mar 23Jun 23Oct 23Jan 24Feb 26Sep 26
AMRX Price to Book by year
PeriodPrice to Book
Sep 2646.41
Sep 2647.59
Aug 2647.86
Aug 2648.87
Aug 2649.53
Aug 2649.5
May 26674.24
Apr 26657.95
Apr 26731
Apr 26659
Apr 26655.85
Mar 26622.74
Mar 26621.69
Mar 26621.69
Mar 26695.79
Feb 26725.74
May 2426.87
Apr 2423.34
Apr 2421.55
Apr 2421.94
Apr 2424.33
Mar 2424.09
Mar 2424.13
Mar 2421.87
Mar 244.54
Mar 244.61
Feb 244.89
Feb 244.97
Feb 244.7
Feb 244.65
Jan 244.63
Jan 244.55
Jan 244.55
Jan 245.05
Dec 235.12
Dec 234.86
Dec 234.38
Dec 234.27
Dec 233.93
Nov 233.81
Nov 233.82
Nov 233.56
Nov 233.61
Oct 233.17
Oct 232.92
Oct 233.23
Oct 233.52
Sep 233.55
Sep 233.52
Sep 233.46
Sep 233.17
Sep 233.55
Aug 233.29
Aug 233.14
Aug 233.34
Aug 233.85
Jul 232.96
Jul 233.16
Jul 232.84
Jul 232.94
Jun 232.91
Jun 232.7
Jun 232.54
Jun 232.29
Jun 232.39
May 232.13
May 232.17
May 231.8
May 231.39
Apr 231.4
Apr 231.18
Apr 230.99
Apr 231.02
Mar 231.01
Mar 230.96
Mar 231.04
Mar 231.11
Mar 231.39
Feb 231.52
Feb 231.7
Feb 231.6
Feb 231.7
Jan 231.5
Jan 231.47
Jan 231.55
Jan 231.54
Dec 221.39
Dec 221.54
Dec 221.56
Dec 221.61
Dec 221.7
Nov 221.67
Nov 221.57
Nov 221.72
Nov 221.68
Oct 221.85
Oct 221.68
Oct 221.55
Oct 221.68
Sep 221.6
Amneal Pharmaceuticals, Inc.
AMRX
Stockpicker

Video analysis: AMRX

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: AMRX

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

zacks.com · 27 Aug 2026

5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low

COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

zacks.com · 20 Aug 2026

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

businesswire.com · 19 Aug 2026

STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)---- $AMRX #AMRX--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company's current shareholders.The investigation seeks to determine whether Amneal or the company's officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional informat.

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

zacks.com · 18 Aug 2026

5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns

Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

zacks.com · 12 Aug 2026

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

zacks.com · 12 Aug 2026

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

zacks.com · 12 Aug 2026

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

zacks.com · 11 Aug 2026

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.